Global biotech developing and selling cancer therapies, including its own BTK-inhibitor drug, renamed from BeiGene in 2025.
Global biotech developing and selling cancer therapies, including its own BTK-inhibitor drug, renamed from BeiGene in 2025.
Most revenue is Brukinsa, sold mainly in the US and Europe by its own sales teams, with the PD-1 drug Tevimbra selling mainly in China and Europe. Its legal base moved to Switzerland in 2025 when it renamed from BeiGene to BeOne. This is the Shanghai-listed A share.
Moat: narrow (IP / patents, regulatory licence). Patent-protected, globally approved oncology drugs with an expanding commercial and pipeline base.
Headquarters: Beijing, China / Basking Ridge, US (dual HQ) · Founded: 2010 · Employees: 12,000
Size BeOne Medicines (688235.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $45.5B, the 36th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥273.57 on 18 Nov 2026.
Performance Over six months the shares gained 8.6%, against +16.9% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 24.6% over the last twelve months (peer median +11.7%); the operating margin is 17.9% (peer median 21.3%).
Valuation It trades at 59.7× forward earnings against a peer median of 19.0× (2nd most expensive of 19).
Price implies For today's price to make sense, revenue must grow about 19% a year for seven years (Req g). Recent delivered growth is +79%, so the hurdle is -60 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 35.5 points above its cost of capital (7.8% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥44.2B | CN¥37.4B | CN¥27.9B | CN¥17.5B | CN¥9.79B |
| Revenue growth | — | +34% | +60% | +79% | — |
| Gross profit | CN¥38.6B | CN¥31.9B | CN¥22.7B | CN¥14.2B | CN¥7.38B |
| EBITDA | CN¥9.08B | CN¥4.12B | -CN¥2.91B | -CN¥7.97B | -CN¥11.9B |
| Net income | CN¥6.13B | CN¥2.01B | -CN¥4.73B | -CN¥6.27B | -CN¥13.9B |
| Free cash flow | CN¥9.82B | CN¥6.60B | -CN¥4.64B | -CN¥12.2B | -CN¥12.6B |
| Capital expenditure | CN¥954M | CN¥1.44B | CN¥3.65B | CN¥4.14B | CN¥2.25B |
| Total debt | CN¥13.8B | CN¥14.0B | CN¥7.88B | CN¥6.60B | CN¥4.11B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| BeOne Medicines 688235.SS | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% |
| AstraZeneca AZN.L | $278B | -2% | +5% | 23% | 17.6× | 14.4% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Lilly (Eli) LLY | $1.30T | +36% | +46% | 51% | 29.5× | 6.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688235.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.4% | +7.0% | 9th lowest of 21 |
| 6-month return | +8.6% | +16.9% | 9th lowest of 21 |
| Distance from 52-week high | -14.3% | -7.6% | 8th lowest of 21 |
| Revenue growth (TTM) | +24.6% | +11.7% | 5th highest of 21 |
| Operating margin | 17.9% | 21.3% | 8th lowest of 21 |
| Forward P/E | 59.7× | 19.0× | 2nd most expensive of 19 |
| Growth the price implies (Req g, 7 yrs) | 19.1% | 7.6% | 3rd most demanding of 18 |
| Growth delivered (Del g) | +79.3% | +7.2% | highest of 18 |
| Hurdle (Req g minus delivered) | -60.2 pp | +3.0 pp | least demanding of 18 |
| ROIC minus cost of capital | +35.5 pp | +4.4 pp | 2nd highest of 21 |
| EV / EBITDA | 30.7× | 13.8× | 3rd most expensive of 17 |
| Net debt / EBITDA | -2.8× | 1.3× | 2nd least indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| BeOne Medicines 688235.SS | China | $45.5B | +9% | +25% | 18% | 59.7× | 19.1% | +79.3% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | China | $45.7B | -13% | +6% | 27% | 33.4× | 13.4% | +2.7% |
| Sun Pharmaceutical Industries SUNPHARMA.NS | India | $48.0B | -1% | +12% | 23% | 36.0× | 28.7% | +11.7% |
| Sandoz SDZ.SW | Switzerland | $41.7B | +26% | +1% | 15% | 24.5× | 7.5% | +0.4% |
| Galderma GALD.SW | Switzerland | $51.9B | +18% | +16% | 19% | 45.7× | 18.0% | +6.4% |
| Otsuka Hldgs 4578.T | Japan | $39.9B | +9% | +11% | 18% | 16.8× | 1.6% | +11.7% |
| Haleon HLN.L | United Kingdom | $39.6B | 0% | +1% | 23% | 16.4× | 5.2% | +2.2% |
| Royalty Pharma RPRX | United States | $39.4B | +29% | +11% | 66% | 11.5× | 10.8% | +2.3% |
| Biogen BIIB | United States | $37.2B | +34% | +2% | 17% | 17.1× | 10.1% | -5.1% |
| Zoetis ZTS | United States | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% | +7.2% |
| Bayer BAYN.DE | Germany | $60.3B | +48% | 0% | 13% | 12.3× | n/a | n/a |
| Wuxi Apptec 2359.HK | Hong Kong | $64.1B | +51% | +38% | 44% | 19.5× | 8.4% | +20.4% |
| Astellas Pharma 4503.T | Japan | $31.4B | +17% | +19% | 23% | 12.9× | -9.0% | +11.4% |
| Daiichi Sankyo 4568.T | Japan | $31.4B | +8% | +17% | 13% | 18.4× | 7.6% | +17.1% |
| Divi's Laboratories DIVISLAB.NS | India | $31.3B | +60% | +22% | 34% | 73.5× | 47.1% | +8.9% |
| Takeda Pharmaceutical 4502.T | Japan | $69.8B | +30% | +6% | 18% | 51.0× | 3.7% | +7.1% |
| Merck KGaA MRK.DE | Germany | $71.3B | +16% | +1% | 19% | 17.4× | 7.4% | +3.8% |
| Roivant Sciences ROIV | United States | $28.1B | +20% | +102% | -3,234% | n/a | n/a | n/a |
| Chugai Pharmaceutical 4519.T | Japan | $75.2B | -8% | +17% | 50% | 23.7× | 5.0% | +9.8% |
| Insmed INSM | United States | $26.3B | +3% | +240% | -42% | n/a | n/a | n/a |
| Hansoh Pharma 3692.HK | Hong Kong | $25.3B | -3% | +25% | 38% | 25.8× | 7.9% | +10.8% |